Key result
Duplex ultrasound screening for asymptomatic carotid stenosis adds QALYs at ~$39,500 per QALY gained.
Why the study?
The most appropriate screening strategy for asymptomatic carotid stenosis remains unclear despite established benefit of carotid endarterectomy for patients with >60% stenosis.
Is duplex ultrasound screening for asymptomatic carotid stenosis cost-effective in 60-year-old patients?
Is duplex ultrasound screening for asymptomatic carotid stenosis cost-effective in 60-year-old patients?
Duplex ultrasound screening for asymptomatic carotid stenosis can be cost-effective ($39,495/QALY) under specific conditions, including high test specificity and performance in centers of excellence.
Answers are grounded in this paper and cite their sources.
Screening may be cost-effective only in centers of excellence; leaves open value of routine ultrasound screening in unselected populations.
PURPOSE: The benefit of carotid endarterectomy for patients who are asymptomatic with > 60% carotid stenosis has been established by the Asymptomatic Carotid Atherosclerosis Study (ACAS). Which screening strategy is most appropriate is still unclear. This study assessed the cost-effectiveness of ultrasound screening for asymptomatic carotid stenosis. METHODS: Cost-effectiveness analysis was performed with a Markov model and with data from ACAS and other studies. RESULTS: For 60-year-old patients with a 5% prevalence of 60% to 99% asymptomatic stenosis, duplex ultrasound screening increased average quality-adjusted life years (QALY; 11.485 vs 11.473) and lifetime cost of care ($5500 vs $5012) under base-case assumptions. The incremental cost per QALY gained (cost-effectiveness ratio) was $39,495. Screening was cost-effective with the following conditions: disease prevalence was 4.5% or more, the specificity of the screening test (ultrasound) was 91% or more, the stroke rate of patients who were medically treated was 3.3% or more, the relative risk reduction of surgery was 37% or more, the stroke rate associated with surgery was 160% or less than that of the North American Symptomatic Carotid Endarterectomy Trial or ACAS perioperative complication rates, and the cost of ultrasound screening was $300 or less. A one-time screening, compared with a screening every 5 years, had more QALY (11.485 vs 11.482) and lower cost ($5500 vs $5790). Screening without arteriography, compared with screening with arteriographic verification, provided few additional QALYs (11.486 vs 11.485) at additional cost ($6896 vs $5500). The cost-effectiveness ratio was sensitive to assumptions about the stroke rate of patients who were asymptomatic and other variables. CONCLUSIONS: Screening for asymptomatic carotid stenosis can be cost-effective when both screening and carotid endarterectomy are performed in centers of excellence.
No takes yet. Share an insight, caveat, or question.
Yin et al. (1998) studied Asymptomatic carotid stenosis. Duplex ultrasound screening vs. No screening was evaluated on Quality-adjusted life years (QALY) (ICER $39,495 per QALY gained). Duplex ultrasound screening for asymptomatic carotid stenosis in 60-year-old patients increased average QALYs with an incremental cost-effectiveness ratio of $39,495 per QALY.
Synapse has enriched 10 related papers. Consider them for comparative context: